38 Result(s)

Article

Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations

Chemoimmunotherapy with combined fludarabine, cyclophosphamide and rituximab (FCR) has been an effective treatment for patients with chronic lymphocytic leukemia (CLL). We initiated a phase II trial for previo...

Nitin Jain, Philip Thompson, Jan Burger, Alessandra Ferrajoli, Koichi Takahashi… in Leukemia (2021)

Article

Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib

Jennifer R. Brown, Andrew Zelenetz, Richard Furman, Nicole Lamanna… in Leukemia (2020)

Article

Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors

Patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) have near-normal life expectancies. With this comes the possibility of develo** second cancers; we aimed to evaluat...

Koji Sasaki, Hagop M. Kantarjian, Susan O’Brien… in International Journal of Hematology (2019)

Chapter

Clinical Evaluation and Management of Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is the most leukemia in the United States and is characterized by clonal expansion of CD5-positive B cells. The diagnosis of CLL requires the presence of greater than or equa...

Nitin Jain, Susan O’Brien in Concise Guide to Hematology (2019)

Article

Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy

During the past 5 years, a number of highly active novel agents, including kinase inhibitors targeting BTK or PI3Kδ, an antagonist of the antiapoptotic protein BCL-2, and new anti-CD20 monoclonal antibodies, h...

Jan A. Burger, Susan O’Brien in Nature Reviews Clinical Oncology (2018)

Article

Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR–ABL kinase domain mutations

Kinase domain (KD) mutations of ABL1 represent the most common resistance mechanism to tyrosine kinase inhibitors (TKI) in CML. Besides T315I, mutations in codon 255 are highly resistant mutations in vitro to ...

Kiran Naqvi, Jorge E. Cortes, Raja Luthra… in International Journal of Hematology (2018)

Article

A targeted treatment with off-target risks

It emerges that blood-cancer-targeting drugs that block a tumour-survival pathway also activate a mutation-causing enzyme in mice and in human cells. This might have implications for the clinical use of these ...

David A. Fruman, Susan O'Brien in Nature (2017)

Article

Chronic lymphocytic leukaemia

Chronic lymphocytic leukaemia (CLL) is a malignancy of CD5⁺ B cells that is characterized by the accumulation of small, mature-appearing lymphocytes in the blood, marrow and lymphoid tissues. Signalling via surfa...

Thomas J. Kipps, Freda K. Stevenson, Catherine J. Wu… in Nature Reviews Disease Primers (2017)

Article

Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies

Ibrutinib is an oral Bruton’s tyrosine kinase inhibitor, recently approved for the treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) patients with at least one prior therapy. We d...

Eleonora Marostica, Juthamas Sukbuntherng… in Cancer Chemotherapy and Pharmacology (2015)

Article

Novel Therapeutic Strategies in Adult Acute Lymphoblastic Leukemia – A Focus on Emerging Monoclonal Antibodies

The outcomes in adult B-cell acute lymphoblastic leukemia (ALL) remain inferior to those achieved in pediatric populations. Targeted therapy with monoclonal antibodies may improve outcomes in adult B-cell ALL ...

Naval Daver, Susan O’Brien in Current Hematologic Malignancy Reports (2013)

Article

Philadelphia-Positive Acute Lymphoblastic Leukemia: Current Treatment Options

The Philadelphia chromosome (Ph), t(9;22), is seen in about 20 % to 30 % of adults diagnosed with acute lymphoblastic leukemia (ALL). It has been associated with poorer prognosis compared with Ph-negative ALL....

Theresa Liu-Dumlao, Hagop Kantarjian, Deborah A. Thomas… in Current Oncology Reports (2012)

Article

The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells

The prognosis of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) is poor. Chemotherapy is rarely curative and tyrosine kinase inhibitors (TKIs) induce only transient res...

Wei-Gang Tong, Zeev Estrov, Yongtao Wang, Susan O’Brien… in Investigational New Drugs (2011)

Article

Role of Tyrosine Kinase Inhibitors in the Management of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

The Philadelphia chromosome is the most common cytogenetic abnormality found in adult patients diagnosed with acute lymphoblastic leukemia. The result of this abnormality is the BCR-ABL protein, a constitutive...

Michael S. Mathisen, Susan O’Brien… in Current Hematologic Malignancy Reports (2011)